Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about glymphatic_system: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
Knowledge base pages for this entity
| Target | Relation | Type | Str |
|---|---|---|---|
| No outgoing edges | |||
| Source | Relation | Type | Str |
|---|---|---|---|
| H2 | enhances_clearance | hypothesis | 0.00 |
| PMID_32155360 | human_validation_inconsistent | publication | 0.00 |
| AQP4 | regulates | gene | 0.70 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Glymphatic System-Enhanced Antibody Clearance Reversal | 0.537 | neurodegeneration | Blood-brain barrier transport mechanisms |
Scientific analyses that reference this entity
neurodegeneration | 2026-04-26 | 7 hypotheses Top: 0.580
clinical neurology | 2026-04-08 | 0 hypotheses
neurodegeneration | 2026-04-07 | 7 hypotheses Top: 0.690
neurodegeneration | 2026-04-07 | 7 hypotheses Top: 0.690
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| s:** - Test tau spreading in AQP4 knockout vs wild-type mice with PSP/ | falsification | Neurodegeneration | 0.400 | 0.50 | mouse | proposed | $260,000 |
| Glymphatic-Circadian Axis Enhancement Therapy for Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs AD with Co | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| NPH Glymphatic System Interaction Experiment | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $5,460,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Characteristics of MRI lesions in AQP4 antibody-positive NMOSD, MOGAD, and multi [PMID:40773034] | Leitner U, Chew SH, Blanch J, Viswanatha | J Neurol | 2025 | 1 |
| B cell and aquaporin-4 antibody relationships with neuromyelitis optica spectrum [PMID:39222408] | Bennett JL, Pittock SJ, Paul F, Kim HJ, | Ann Clin Transl Neurol | 2024 | 1 |
| Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic str [PMID:34530847] | Carnero Contentti E, Correale J | J Neuroinflammation | 2021 | 1 |
| Ganglion Cell Layer Compared With Inner Plexiform Layer Atrophy After Optic Neur [PMID:41881459] | Filippatou AG, Gakis G, Bacchetti A, Kim | Neurology(R) neuroimmunology & | 2026 | 0 |
| β-Hydroxybutyrate improves glymphatic system function and alleviates cerebral ed [PMID:41535708] | Yu MJ, Xiong RQ, Wu JW, Li YC, Xie JX et | Acta Pharmacol Sin | 2026 | 0 |
| CCR2 knockdown attenuates post-hemorrhagic hydrocephalus and improves glymphatic [PMID:41539459] | Deng H, Zhang S, Wang H, Liu X, Zhong K | Exp Neurol | 2026 | 0 |
| Neutrophil-microglia interaction drives motor dysfunction in a neuromyelitis opt [PMID:41665955] | Qi F, Lennon VA, Zhao S, Guo Y, Ding H e | J Clin Invest | 2026 | 0 |
| Safety and efficacy of ravulizumab in patients with NMOSD previously treated wit [PMID:41782198] | Bennett JL, Bhattacharyya S, Zabeti A, L | Mult Scler | 2026 | 0 |
| NMOSD and MOGAD: Updates on diagnostic criteria. [PMID:41927386] | Marignier R, Leal Rato M | Rev Neurol (Paris) | 2026 | 0 |
| Therapeutic updates in NMOSD and MOGAD: From present practice to future promise. [PMID:41927387] | Elosua-Bayés I, Cobo-Calvo A | Rev Neurol (Paris) | 2026 | 0 |
| Recurrent aquaporin 4-immunoglobulin G-positive neuromyelitis optica spectrum di [PMID:41915816] | Jiang X, Chen J, Wen Y, Yuan L, Zhang J | The Journal of international m | 2026 | 0 |
| Glymphatic System Dysfunction in Central Nervous System Diseases. [PMID:41792880] | Zahran A, Abu-Khazneh O, Bdair M, Hajjeh | CNS neuroscience & therapeutic | 2026 | 0 |
| Diagnostic Value of the Kappa Free Light Chain Index to Distinguish MOGAD, NMOSD [PMID:41921124] | Tournier A, Gavoille A, Pique J, Levraut | Neurology | 2026 | 0 |
| Mapping the Brain's Glymphatic System. [PMID:41751308] | Voumvourakis K, Thomaidis NS, Tsiodras S | Biomedicines | 2026 | 0 |
| Frequency of AQP4 and MOG Antibodies in Patients With Optic Neuritis Fulfilling [PMID:41843863] | Deschamps R, Papeix C, Demortiere S, Lar | Neurology | 2026 | 0 |
| A compound pulsed magnetic field achieves superior cognitive benefits against Al [PMID:41856031] | Wang X, Wang X, Zhao H, Zhao C, Wang P, | Neurotherapeutics : the journa | 2026 | 0 |
| Physical exercise as a non-pharmacological strategy to enhance glymphatic functi [PMID:41676384] | Ghayourvahdat A, Azimizonuzi H, Ahmed M | IBRO neuroscience reports | 2026 | 0 |
| Brominated flame retardants in black plastic kitchen utensils: Concentrations an [PMID:28847134] | ["Kuang J", "Abdallah M", "Harrad S"] | The Science of the total envir | 2018 | 0 |
| Genome-wide association study of 40,000 individuals identifies two novel loci as [PMID:27329760] | ["Hou L", "Bergen S", "Akula N", "Song J | Human molecular genetics | 2016 | 0 |
| Immunohistochemical evidence for the association between attenuated mTOR signali [PMID:25186104] | ["Saito R", "Yanai M", "Miki Y", "Fukasa | The Tohoku journal of experime | 2014 | 0 |
Multi-agent debates referencing this entity
closed · Rounds: 4 · Score: 1.00 · 2026-04-26
closed · Rounds: 4 · Score: 0.76 · 2026-04-21
closed · Rounds: 4 · Score: 0.76 · 2026-04-21
closed · Rounds: 4 · Score: 0.79 · 2026-04-09
Hypotheses and analyses mentioning glymphatic_system in their description or question text
No additional research found